NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will ...

NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food ...

Food allergies affect more than 220 million people worldwide, including approximately 33 million people in the United States. Management of food allergies currently focuses on avoidance of exposure to ...

Today, Intrommune Therapeutics, Inc. is excited to announce the publication of a its Phase 1 OMEGA (Oral Mucosal Escalation Goal Assessment) study evaluating the safety, tolerability, and adherence of ...

In the fourth episode of Unicorn Hunters (a show that gives viewers not only a deeper look into the sort of conversations that take place between powerful investors and entrepreneurs, but also allows ...

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- As the burden of food allergies continues to increase each year, the need for safe, effective, and convenient treatments has never been greater. Over 33 ...

For the roughly 1.5 million children living with peanut allergies, decreasing sensitivity could one day be as easy as brushing your teeth. That's the plan for Intrommune, a new New York-based ...

New York, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics will attend and present at the upcoming Biotech Showcase™, which occurs during the annual J.P. Morgan Biotechnology Healthcare ...

NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The global burden of food allergy has increased exponentially over the past few decades and represents a significant health concern. In the United States ...

Intrommune Therapeutics welcomes an independent editorial that was recently published in Annals of Allergy, Asthma & Immunology which underscores the potential of its innovative Oral Mucosal ...